Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

How SMSFs are staying ahead of the curve

Jessica Amir
September 30, 2020

Morning Bell 30 September

Jessica Amir
September 30, 2020

Morning Bell 29 September

Jessica Amir
September 29, 2020

Morning Bell 28 September

Jessica Amir
September 28, 2020

Weekly Wrap 25 September

Jessica Amir
September 25, 2020

Morning Bell 25 September

Jessica Amir
September 25, 2020

Morning Bell 24 September

Jessica Amir
September 24, 2020

Morning Bell 23 September

Jessica Amir
September 23, 2020

Morning Bell 22 September

Jessica Amir
September 22, 2020

Morning Bell 21 September

Jessica Amir
September 21, 2020

Weekly Wrap 18 September

Jessica Amir
September 18, 2020